Health Security is a $15.2 billion market
Medical countermeasures for biological, chemical, radiological and nuclear attacks, as well as vaccines, therapeutics and diagnostics for emerging infectious diseases
For general inquiries, please visit our contact page. For mpox inquiries, please contact us at mpox@siga.com
(Note: Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus; TPOXX is approved by the U.S. FDA and Health Canada for the treatment of smallpox. TPOXX, Tecovirimat-SIGA is not approved as a treatment for mpox outside of the EU and UK.)
Apr 1, 2024
Mar 25, 2024
Mar 12, 2024